Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.2452W HIGH $37.50
Volume
1.39 M
Value Traded
46.23 M
Short % Float
7.92%
+0.27%Week
-6.48%1 Month
-31.24%3 Month
+2.53%6 Month
-27.18%5 Year
-20.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.61 B
EPS (TTM)
-1.36
P/E Ratio
-
Ent. Value
5.01 B
Total Shares
193.77 M
Float Shares
184.80 M
Insiders
4.63%
Institutions
51.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LEGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Legend Biotech Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Legend Biotech Corporation
413Total events
3Upcoming
89Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingCorporate
Legend Biotech launches inaugural ELITE grant program for CAR-T innovation in multiple myeloma
multiple myelomasource ↗
▲Full ResultsCARVYKTIApprovedClinical Data
Five-year follow-up data from CARTITUDE-2 Cohort A presented at 2026 IMS Annual Meeting
relapsed/refractory multiple myeloma (RRMM)source ↗
▲Oral PresentationCARVYKTIApprovedPresentation
CARVYKTI five-year CARTITUDE-2 Cohort A data presented at 2026 IMS Annual Meeting
relapsed/refractory multiple myeloma (RRMM)source ↗
▲Long Term DataCARVYKTIApprovedClinical Data
Five-year follow-up data from CARTITUDE-2 Cohort A presented at 2026 IMS Annual Meeting
relapsed/refractory multiple myeloma (RRMM)source ↗
▼Safety Data UpdateCARVYKTIApprovedClinical Data
Longer-term safety profile consistent with known CARVYKTI profile; one new AML and two deaths reported
relapsed/refractory multiple myeloma (RRMM)source ↗
◆Poster Presentationcilta-celApprovedPresentation
eMMpower-CART: Real-World Insights into Early-Line Cilta-cel Outcomes in Multiple Myeloma (MM)
multiple myelomasource ↗
●Management ChangeCorporate
Alan Bash served as Interim CEO and resumes role as President, CARVYKTI
▼Equity OfferingCorporate
Pricing of underwritten public offering of 7,700,000 ADSs at $29.35 per ADS
▲Topline ReadoutLB2501Clinical Data
Topline data from Phase 1 study of LB2501: 100% ORR and 83.3% CR at DL2
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲Primary Endpoint MetLB2501Clinical Data
Primary endpoint of safety met: no DLTs, SAEs, ICANS, or deaths
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲Oral PresentationLB2501Presentation
Late-breaking oral presentation at EHA 2026
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲Late-BreakerLB2501Presentation
Late-breaking presentation of LB2501 proof-of-concept data at EHA 2026
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲Topline ReadoutLB2501Clinical Data
Proof-of-concept data: 100% ORR and 83.3% CR at DL2
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
◆Oral PresentationLB2501Presentation
Oral presentation at EHA 2026 of Phase 1 data for LB2501
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
◆Poster PresentationCARVYKTIApprovedPresentation
CARTITUDE-4 cytogenetic subgroup analysis of patients responding to bridging therapy
multiple myelomasource ↗
◆Oral PresentationLB2102Presentation
First-in-human clinical data for LB2102 presented at ASCO 2026
relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC)source ↗
◆Oral PresentationCARVYKTIApprovedPresentation
Multi-study analysis of IEC-associated enterocolitis presented at ASCO 2026
multiple myelomasource ↗
◆Oral PresentationLB2102Presentation
Preliminary Phase 1 data for LB2102 in a rapid oral presentation at ASCO 2026
relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC)source ↗
▲Product LaunchCARVYKTIApprovedPost-Market
Launched CARVYKTI in Italy, Poland, Czech Republic, and Australia
relapsed or refractory multiple myelomasource ↗
▲Topline ReadoutLB2501Clinical Data
Phase 1 topline data for LB2501 (data cutoff April 1, 2026)
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
▲Milestone PaymentCARVYKTIApprovedCorporate
Achieved $55 million milestones under Janssen Agreement
relapsed or refractory multiple myelomasource ↗
◆Topline ReadoutClinical Data
First-in-human data expected for in vivo dual CD20/CD19-targeted cell therapy
non-Hodgkin lymphomasource ↗
●IND SubmissionIND
Multiple IND filings for oncology and autoimmune indications
oncology and autoimmune indicationssource ↗
●Oral PresentationCARVYKTIApprovedPresentation
Presented data at 2026 Tandem Meetings of ASTCT and CIBMTR
multiple myelomasource ↗
◆Poster PresentationCARVYKTIApprovedPresentation
Quality-Adjusted Survival Analysis of Neurologic Events with Cilta-Cel Versus Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population
multiple myelomasource ↗
◆Oral PresentationPresentation
Legend Biotech CEO to present at 44th Annual J.P. Morgan Healthcare Conference
▲Milestone PaymentCARVYKTIApprovedCorporate
Milestone payment of $4.9 million achieved under Janssen Agreement
multiple myelomasource ↗
▲Manufacturing MilestoneCARVYKTIApprovedCMC / Inspection
Completed expansion of Raritan manufacturing facility
multiple myelomasource ↗
▲Enrollment MilestoneCARVYKTIApprovedTrial
Surpassed 10,000 patients treated with CARVYKTI
multiple myelomasource ↗
●Oral PresentationCARVYKTIApprovedPresentation
Presented data from CARTITUDE-1 and CARTITUDE-4 at ASH 2025
multiple myelomasource ↗
●Oral PresentationLucar-G39DPresentation
Presented first-in-human results for LUCAR-G39D
B-cell non-Hodgkin lymphomasource ↗
◆Poster PresentationCARVYKTIApprovedPresentation
Poster: Quality-adjusted Survival Analysis of Neurologic Events with Ciltacabtagene Autoleucel (cilta-cel) vs Standard of Care (SOC) in Patients (Pts) with Lenalidomide-refractory Multiple Myeloma (MM) who Received 1–3 Prior Lines of Therapy (LOT): CARTITUDE-4 Trial Population (Pop)
multiple myelomasource ↗
◆Poster PresentationCARVYKTIApprovedPresentation
Poster: Comparative Efficacy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone and Versus Belamaf, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Previously Treated with 1–3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
multiple myelomasource ↗
◆Oral PresentationCARVYKTIApprovedPresentation
Oral presentation: Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With Better Immune Fitness and Stronger Immune Effects as Shown by Correlative Analysis of Peripheral Blood and the Bone Marrow Tumor Microenvironment (TME) From the CARTITUDE-4 Study
multiple myelomasource ↗
◆Oral PresentationLucar-G39DPresentation
Oral presentation: A Phase 1 Study of Lucar-G39D: A Novel Anti-CD20/CD19 Dual-CAR Allogeneic Gamma Delta T Cells in Adults with Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma (NHL)
relapsed/refractory B-cell non-Hodgkin lymphomasource ↗
◆Poster PresentationCARVYKTIApprovedPresentation
Poster: Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients with Relapsed, Lenalidomide-Refractory Multiple Myeloma
multiple myelomasource ↗
▲Topline ReadoutCARVYKTIApprovedClinical Data
Updated results from CARTITUDE-4: median follow-up 33.6 months
relapsed/refractory multiple myelomasource ↗
▲Full ResultsCARVYKTIApprovedClinical Data
Long-term data from CARTITUDE-1: mPFS 50.4 months in triple-class-exposed patients
relapsed/refractory multiple myelomasource ↗
Past FDA Catalysts and PDUFA Decisions
How LEGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-11 | LB2501 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$444M
Pipeline Value
$4.2B
Commercial Value
Fair Value
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 66%
Small Cap(rank 435 of 658)
Percentile Rank
Legend Biotech Corporation faces pipeline headwinds (31/100), with $758M risk-adjusted pipeline value, led by LUCAR-DKS1 in Relapsed/Refractory Autoimmune Diseases (Phase 1).
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025) Revenue $1.0B x 4.1 = $4.2B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LUCAR-DKS1 Cell therapyNCT07095075 | Relapsed/Refractory Autoimmune Diseases | Phase 1 | RECRUITING | 36 | Dec 31, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every LEGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CARVYKTI BreakthroughOrphan | relapsed/refractory multiple myeloma | 2026-09-25 | five year progression free: 50%; overall survival rate: 69.2%; median pfs: 60.5 monthsRead More | Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single InfusionRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D.Director | Sell | -27,370 52,731 held | $9.46 | 09/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LEGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 4.8 % (166.7 %) | 86.67 M | 3.00 M | 90.4% ( 1.42 M) |
LEGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LEGN ranks across every disease it competes in
Competitive Position is a premium feature
See how LEGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLEGN News
LEGNLegend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
Legend Biotech has launched its inaugural ELITE Program, aimed at supporting early-career healthcare professionals in advancing cell therapy research for multiple myeloma. The program will award grants in two categories: Emerging Educator and Emerging Innovator. Applications are open until November 20, 2026, with recipients announced in December 2026.
Read more →LEGNLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
Legend Biotech presented five-year follow-up data from the CARTITUDE-2 study, showing that 50% of patients with relapsed/refractory multiple myeloma remained alive and progression-free after a single CARVYKTI infusion. The overall survival rate reached 69.2%, highlighting the treatment's potential curative effects. These results suggest that earlier administration of CARVYKTI may enhance long-term remission rates.
Read more →LEGNLegend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Legend Biotech has appointed Ingrid Zhang as its new Chief Executive Officer, effective September 15, 2026. She succeeds Alan Bash, who served as Interim CEO. Zhang, previously Chief Commercial Officer at Novartis, is expected to drive the company's growth and innovation in cell therapy. The Board expressed confidence in her leadership capabilities.
Read more →LEGNLegend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
Legend Biotech will present updated long-term data from the CARTITUDE-2 clinical trial and real-world evidence regarding CARVYKTI at the International Myeloma Society Annual Meeting in Glasgow. These presentations aim to enhance understanding of CARVYKTI's efficacy and safety in treating lenalidomide-refractory multiple myeloma. The data reflects ongoing commitment to improving clinical practices in this field.
Read more →LEGNLegend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
Legend Biotech Corporation announced its participation in the Morgan Stanley Global Healthcare Conference, where interim CEO Alan Bash will engage in a fireside chat. The event is scheduled for September 15, 2026, and will be accessible via a live webcast. This participation underscores Legend Biotech's commitment to advancing cell therapy and engaging with investors.
Read more →LEGN▲ +5.7%on this news
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Legend Biotech reported a 50% increase in net trade sales of CARVYKTI, reaching approximately $657 million in the second quarter of 2026. The company expanded CARVYKTI's availability to 348 sites across 19 global markets, including a successful launch in Ireland. Additionally, Legend achieved its first clinical proof-of-concept for LB2501.
Read more →LEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Legend Biotech Corporation will hold an investor conference call on August 11, 2026, to discuss its second quarter financial results. Senior management will present an overview of the company's performance during the quarter. A live audio webcast will be available, and a replay will be accessible shortly after the call concludes.
Read more →LEGN▼ -13.3%on this newsshared move
Legend Biotech Announces CEO Transition
Legend Biotech announced the resignation of CEO Ying Huang, effective July 24, 2026. Alan Bash, previously President of the CARVYKTI Business Unit, has been appointed as Interim CEO. The Board is conducting a search for a permanent successor while ensuring continuity in leadership and operations. Huang will remain as an advisor through August to aid the transition.
Read more →LEGN▼ -16.7%on this news
Legend Biotech Corporation Announces Pricing of Public Offering
Legend Biotech Corporation has announced the pricing of a public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 each, aiming to raise about $226 million. The offering includes an option for underwriters to purchase an additional 1.155 million ADSs. The transaction is set to close on June 23, 2026, pending customary conditions.
Read more →LEGN▼ -16.7%on this newsshared move
Legend Biotech Corporation Announces Proposed Public Offering
Legend Biotech Corporation has announced a proposed public offering of $225 million of American Depositary Shares (ADSs). The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. This move aims to bolster the company's financial resources amidst market uncertainties.
Read more →LEGNLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech has announced successful early clinical trial results for LB2501, a first-in-class in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. In a Phase 1 study, the treatment demonstrated a remarkable 100% objective response rate and an 83.3% complete response rate among patients at the higher dose level. The therapy exhibited a favorable safety profile, with no serious adverse events reported. Results were shared at the EHA 2026 Congress, marking a significant step in the advancement of cell therapy.
Read more →LEGN▲ +42.2%on this news
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech announced promising Phase 1 results for LB2501, its investigational CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma, which will be presented at EHA 2026. The study reported a 100% overall response rate and an 83.3% complete response rate across two dose levels. Initial findings indicate that the therapy can expand CAR-T cells in vivo without necessitating prior chemotherapy. Importantly, the treatment demonstrated a favorable safety profile, with no dose-limiting toxicities, although some patients experienced infusion-related reactions and cytokine release syndrome.
Read more →LEGN▼ -6.1%on this news· ran to +34% by day 1shared move
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Legend Biotech presented first-in-human results for LB2102, a CAR-T therapy targeting DLL3 in solid tumors, at ASCO 2026. The therapy showed a 28.6% objective response rate and a 78.6% disease control rate among heavily pretreated patients. Additionally, new data on CARVYKTI indicated sustained efficacy and safety in multiple myeloma, reinforcing its role in treatment.
Read more →LEGNLegend Biotech Announces Presentations at ASCO 2026
Legend Biotech announced multiple presentations at the 2026 ASCO Annual Meeting, showcasing preliminary Phase 1 data for LB2102 and new findings from the CARTITUDE-4 study. The rapid oral presentation for LB2102 highlights its potential in treating solid tumors, while additional data on CARVYKTI emphasizes its efficacy in multiple myeloma. The company also plans an investor relations event during the conference.
Read more →LEGN▲ +10.5%on this news
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
Legend Biotech reported a strong performance for Q1 2026, with CARVYKTI sales rising 62% to approximately $597 million. The therapy is now available in 18 global markets, following recent launches. Despite a net loss of $54.3 million, the company maintains a robust cash position of $834.6 million, supporting its growth and development pipeline.
Read more →LEGN▲ +12.3%on this news
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Legend Biotech has engaged a group of distinguished scientific advisors to guide its strategic direction as it advances its cell therapy pipeline. The advisors, who have extensive expertise in oncology and immunology, will contribute insights on emerging science and clinical development. This initiative aims to enhance innovation and expand patient access to next-generation therapies.
Read more →LEGNLegend Biotech to Host Investor Conference Call on First Quarter 2026 Results
Legend Biotech Corporation will hold an investor conference call on May 12, 2026, to discuss its first quarter financial results. The call will include an overview of the company's financial performance by senior management. A live audio webcast will be available, along with a replay and earnings press release on their website.
Read more →About Legend Biotech Corporation
BIOPHARMAWATCH ELITE PLUS
Trade the next LEGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime